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Abstract
The success of tissue engineering depends on the rapid and efficient formation of a functional
blood vasculature. Adult blood vessels comprise endothelial cells and perivascular mural cells that
assemble into patent tubules ensheathed by a basement membrane during angiogenesis. Using
individual vessel components, we characterized intra-scaffold microvessel self-assembly efficiency
in a physiological in vivo tissue engineering implant context. Primary human microvascular
endothelial and vascular smooth muscle cells were seeded at different ratios in poly-L-lactic
acid (PLLA) scaffolds enriched with basement membrane proteins (Matrigel) and implanted
subcutaneously into immunocompromised mice. Temporal intra-scaffold microvessel formation,
anastomosis and perfusion were monitored by immunohistochemical, flow cytometric and
in vivo multiphoton fluorescence microscopy analysis. Vascularization in the tissue-engineering
context was strongly enhanced in implants seeded with a complete complement of blood vessel
components: human microvascular endothelial and vascular smooth muscle cells in vivo assembled
a patent microvasculature within Matrigel-enriched PLLA scaffolds that anastomosed with the
host circulation during the first week of implantation. Multiphoton fluorescence angiographic
analysis of the intra-scaffold microcirculation showed a uniform, branched microvascular network.
3D image reconstruction analysis of human pulmonary artery smooth muscle cell (hPASMC)
distribution within vascularized implants was non-random and displayed a preferential perivascular
localization. Hence, efficient microvessel self-assembly, anastomosis and establishment of a
functional microvasculture in the native hypoxic in vivo tissue engineering context is promoted
by providing a complete set of vascular components. Copyright  2010 John Wiley & Sons, Ltd.
Received 5 March 2010; Accepted 20 May 2010
Supporting information may be found in the online version of this article.
Keywords angiogenesis; scaffold; endothelial; mural cell; microcirculation; multiphoton
1. Introduction
Tissue engineering endeavours to replace and restore
organ function to treat end-stage disease. The success
of tissue engineering strategies depends on the efficient
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formation of a functional blood vasculature to serve the
metabolic needs of bioengineered tissues. However, con-
temporary tissue-engineering approaches are hampered
by inadequate vascularization of the hypoxic engineered
microenviroment that debilitates tissue development
(Muschler et al., 2004; Patterson et al., 2008). Inclusion
of angiogenesis-stimulating factors can improve scaffold
vascularization; however, this process is slow and difficult
to control (Lazarous et al., 1996) Formation of new blood
vessels requires cell–cell and cell–matrix interactions
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between blood vessel components; endothelial cells mural
cells (vascular smooth muscle cells, pericytes) and vascu-
lar basement membrane that collectively regulate vessel
assembly (Black et al., 1998, 1999; Nguyen and D’Amore,
2001). Mural cells define a context comprising heterotypic
cell–cell contact, extracellular matrix (ECM) deposition
and soluble factors that inhibit endothelial proliferation,
maintain capillary diameter, regulate blood flow and pro-
vide survival signals for the cells in the blood vessel
(Hall, 2006; Kutcher and Herman, 2009). Heterotypic
cell–cell contacts at interdigitations between endothe-
lial cells and mural cells provide a unique presentation
context for paracrine factors such as VEGF and angiopoi-
etins, which regulate endothelial cell responses (Darland
and D’Amore, 1999). Hence, the generation of tissue-
engineered microvascular networks in three-dimensional
(3D) matrices, utilizing only vessel-derived endothelial
cells (ECs) or ECs differentiated from progenitor cell pop-
ulations, will depend on the recruitment of host-derived
mural cells, such as vascular smooth muscle cells (SMCs)
for proper vessel maturation (Kaully et al., 2009). Studies
with implanted endothelial spheroids demonstrated that
the investment of engineered vessels by host mural cells
enhances their stability (Alajati et al., 2008; Wenger et al.,
2005). Alternatively, ectopic expression of anti-apoptotic
genes, such as Bcl-2, in microvascular endothelial cells
can improve endothelial survival and microvessel stability
in vivo (Schechner et al., 2000). ECs were shown to form
functional microvessels when co-seeded with mouse mes-
enchymal cells in fibronectin–collagen type I protein gels
(Koike et al., 2004). A functional blood vessel correlates
with the transition of a growing vascular network to a
quiescent vascular phenotype (Adams and Alitalo, 2007).
Our laboratory has previously employed an in vitro organ-
otypic vessel co-culture system in order to model vessel
maturation (Evensen et al., 2009). Endothelial cells co-
cultured with mural cells (SMCs or mesenchymal stem
cells, MSCs) result in a spontaneous endothelial capillary-
like network formation and deposition of a complex
basement membrane leading to an endothelial VEGF-
independent phenotype. We applied the principles defined
by these in vitro results to address whether uniform ves-
sel assembly can be accelerated in a physiological in vivo
tissue-engineering context (Nor et al., 2001). Our results
emphasize the dominant pro-maturation effect of vascu-
lar SMCs that enforces formation of a uniform, branched
functional intra-scaffold microvasculature, providing a
methodological and conceptual basis for improving tissue-
engineering strategies.
2. Materials and methods
2.1. Cells
Human dermal microvascular endothelial cells (HMVECs;
single donor lot, Lonza) were grown in EGM-2 MV
medium (Lonza). Human pulmonary artery smooth
muscle cells (hPASMCs; single donor lot; Lonza) were
grown in SmGm medium (Lonza). Primary cells were
used at passages 3–7. Phoenix A retroviral packaging
cells (ATCC) were grown in Dulbecco’s modified Eagle’s
medium (DMEM), 4500 mg/ml glucose (Sigma-Aldrich)
supplemented with 10% fetal bovine serum (FBS; Euro
Clone/PAA), 5% penicillin–streptomycin (Sigma-Aldrich)
and 5% L-glutamine (Sigma-Aldrich).
2.2. Retroviral transduction
Phoenix A retroviral packaging cells were transfected
with GFP or RFP retroviral vectors (Evensen et al., 2009)
according to Swift et al. (1999). Briefly, subconfluent
Phoenix A cells were transfected by CaCl2 precipitation
in the presence of chloroquine (Sigma-Aldrich). Virus
was harvested in EGM-2 MV or SmGm medium 48 h
post-transfection and added to subconfluent HMVECs
or hPASMCs (passages 3–5) with 5 µg/ml protamine
sulphate (Sigma-Aldrich) for 16 h. Transduced GFP-
expressing HMVECs and RFP-expressing hPASMCs were
purified by flow cytometric sorting on a FACSAria Cell
Sorter (BD Biosciences).
2.3. In vitro organotypic blood vessel system
A microtitre plate format in vitro organotypic blood vessel
system assay was conducted as described (Evensen et al.,
2009). Briefly, 6000 GFP-expressing HMVECs and 50 000
hPASMCs were co-seeded in EGM-2 MV medium in a 96-
well plate. Co-cultures were imaged after 72 h, using a
fully automated high-throughput fluorescence microscope
(BD Pathway 855).
2.4. Experimental animals
For all experiments, non-obese mice with severe com-
bined immunodeficiency disease (NOD/SCID; Gade Insti-
tute/Taconic Farms) were used. The animals were aged
approximately 6–8 weeks at the time of scaffold implan-
tation. All experiments were approved by the Norwegian
Animal Research Authority and conducted according to
the European Convention for the Protection of Vertebrates
Used for Scientific Purposes.
2.5. Scaffold preparation
Poly-L-lactic acid (PLLA) scaffolds were produced by a
solvent-casting particulate-leaching technique, previously
described by Nor et al. (2001). 1 g PLLA (Resomer L
206 S, Boehringer Ingelheim) was dissolved in 20 ml
chloroform (Sigma) to yield a 5% solution. NaCl (Fisher
Scientific) was sieved through a test sieve (Retsch) with
a pore size of 450 µm, and 3.45 g sieved NaCl was
distributed in silanized glass beakers. The NaCl was mixed
with the 5% PLLA solution and the solvent was left to
evaporate. Thereafter, the scaffolds were leached for 48 h
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with double-distilled water to wash out the NaCl, and
then dried and cut into 6 × 6 × 1 mm pieces. The scaffolds
were sterilized in a descending alcohol series from 100%
to 70% EtOH and kept in sterile phosphate-buffered saline
(PBS) until implantation.
2.6. Tissue-engineering model
Prior to implantation, the scaffolds were dried briefly
on sterile paper and filled with a total of 1 × 106
cells in 36 µl 50 : 50 EGM-2 MV and growth factor-
reduced phenol red-free Matrigel (BD). The scaffolds
were left at 37 ◦C for 30 min for the Matrigel to
solidify. The scaffolds were seeded with 1 × 106 HMVECs
alone, 1 : 1 (500 000 HMVECs:500 000 hPASMCs) or 1 : 4
(200 000 HMVECs:800 000 hPASMCs) ratios. For each
experimental group, five mice were implanted with two
scaffolds each. Acellular scaffolds containing Matrigel only
were implanted into four mice, and scaffolds seeded with
1 × 106 hPASMCs only were implanted into five mice to
provide negative controls for histology and imaging.
NOD/SCID mice were anaesthetized with an intramus-
cular injection of 20 µl 1 : 2 concentration of Rompun
(Xylazin; 20 mg/ml; Bayer Health Care):Narketan
(Ketamin; 100 mg/ml; Vétoquinol) in the thigh muscle.
A 2.5 cm incision was made on the back of the mouse
and the scaffolds were placed in skin flaps at the flanks.
After 7, 14 or 21 days, the mice were sacrificed by cer-
vical dislocation after deep Isoflurane (Schering-Plough)
anaesthesia, and the scaffolds were recovered for fixation.
2.7. Histological staining
The scaffolds were fixed in 10% paraformaldehyde (PFA)
and subsequently paraffin-embedded for sectioning. Sec-
tions from the middle part of the scaffold were deparaf-
finized and stained with monoclonal mouse-anti human
CD31 (M0823, Dako), and monoclonal mouse anti-human
smooth muscle actin (M0851, Dako), visualized with 3,3′-
diaminobenzidine tetrahydrochloride (DAB; EnVision
detection system, K5007, Dako) and counterstained with
haematoxylin (DakoREAL Haematoxylin S2020, DAKO).
Antibody specificity was validated using sections from
acellular and hPASMCs-only implants.
2.8. Functional multiphoton fluorescence
microscopy analysis
In order to specifically label perfused human endothelial
cells in the scaffolds, 200 µl UEA1–lectin–FITC (Sigma-
Aldrich; 1 mg/ml in sterile 0.9% NaCl) was injected into
the lateral tail vein 30 min before sacrifice (Holland et al.,
2005) The scaffolds were excised and immediately imaged
using a Multiphoton Microscope (Leica SP5). Acquired
serial images were analysed using 3D image analysis
software (IMARIS 6.3).
2.9. Flow cytometry analysis
Scaffolds were removed 30 min after injection with
UEA1–Lectin–FITC and homogenized using a syringe in
a collagenase A solution (Sigma-Aldrich; 22 U/ml). The
cells were centrifuged at 1000 rpm for 5 min, washed
with PBS and filtered with a 40 µm pore size filter. The
cells were then washed once more, resuspended in PBS
and analysed by flow cytometry for FITC fluorescence.
Propidium iodide staining (1 µg/ml; Molecular Probes)
was performed in order to exclude dead cells from the
analysis.
2.10. Image analysis
To quantify the number of vessels/mm2 and the vessel
diameter, histological sections of scaffolds were examined
with a light microscope (Leica). Using the image-
processing program AnalySIS, the outlines of anti-hCD31-
staining vessels in five fields of view of a section
were encircled manually at ×200 magnification. The
number of vessels from five fields of view was used to
calculate the vessel diameter and number of vessels/mm2.
Vessels were subdivided into five categories based on
diameter, <10, 10–20, 20–30, 30–50 and 50 µm, that are
characteristic for capillary arteriole, artery and immature
vessels (Silverthorn et al., 2004).
Serial multiphoton fluorescence images acquired from
ex vivo scaffolds were reconstructed using 3D image anal-
ysis software (IMARIS 6.3). The length and the diameter
of UEA–lectin–FITC-stained vessels was quantified in
images using IMARIS. Analysis of the mean distance
between human UEA–lectin–FITC stained vessels and
RFP-expressing hPASMCs in the scaffolds was performed
as follows. Binary masks of voxels identified as belong-
ing to vessels or smooth muscle cells (green and red in
Figure 7A) were exported from IMARIS 6.3 as a series of
TIFF images and imported as image stacks into the Fiji dis-
tribution of ImageJ (Rasband, 1997–2008). The distance
of every voxel to the nearest hPASMC/RFP was calculated
by applying the Euclidean distance transformation to the
hPASMC/RFP image stack (Dougherty and Kunzelmann,
2007). The distances for the subset of voxels forming
the surface of the vessels was obtained by applying the
Binary Outline tool to the HMVEC/UEA1–lectin–FITC
image stack and using this to mask the Euclidean distance
map calculated above. This yielded the distance of each
of 159 147 voxels on the vessel surfaces to the nearest
hPASMC/RFP voxel.
2.11. Statistics
The statistical significance of the data was evaluated
using a one-tailed Student’s t-test. Statistically significant
differences are denoted ∗(p < 0.05) or ∗∗(p < 0.01).
Number (n) in each experiment refers to the number
of scaffolds analysed. This number was always 6 or
Copyright  2010 John Wiley & Sons, Ltd. J Tissue Eng Regen Med 2011; 5: e52–e62.
DOI: 10.1002/term
Efficient in vivo vascularization of tissue-engineering scaffolds e55
larger (maximum, n = 12) for the immunohistochemistry
analysis; for the ex vivo imaging, n = 4. All values in bar
diagrams are presented as mean ± standard error of mean
(SEM).
3. Results
3.1. Engineering mature human
microvasculature from vascular components
in vivo
Maturation of nascent blood vessels requires heterotypic
vascular cell–cell interactions (Evensen et al., 2009). We
analysed a microtitre plate format in vitro organotypic
blood vessel system, comprising primary HMVECs
co-cultured in vitro with human pulmonary artery-
derived vascular smooth muscle cells (hPASMCs).
HMVEC–hPASMC co-cultures form extensive capillary-
like networks and deposit a peri-endothelial basement
membrane-like structure comprising vascular collagens
(Figure 1A–C). To determine whether this vessel self-
assembly process can form a functional microvasculature
in an in vivo tissue engineering context, we developed
a tissue-engineering model comprising HMVECs and
hPASMCs co-seeded with soluble basement membrane
proteins (Matrigel) into a PLLA scaffold that is implanted
into the dorsal subcutaneous tissue of an immunodeficient
mouse host context (Nor et al., 2001). Subcutaneous
PLLA scaffold implants become enveloped by connective
tissue within 5 days and anastomose with local host
fascial vessels (Nor et al., 2001). The subcutaneous
microenviroment is hypoxic and thus is a relevant
assessment of microvessel formation efficiency within a
tissue-engineering scaffold (Patterson et al., 2008).
PLLA scaffolds were fabricated with ≥450 µm pores and
seeded with primary human vascular cells and soluble
basement membrane proteins (Figure 2A, B). Primary
human vascular cells attached to the PLLA scaffold
surface within 24 h (Figure 2C). PLLA scaffolds seeded
with HUMVECs in monoculture or HUMVECs and vSMCs
at a 1 : 1 or 1 : 4 ratio were implanted subcutaneously
into immunocompromised NOD-SCID mice. Implants
were retrieved 7, 14 or 21 days post-implantation and
evaluated for the presence of intra-scaffold human
microvasculature by immunohistochemistry, using anti-
human CD31 (Figure 3). Patent vessels stained by anti-
human CD31 were evident throughout scaffolds seeded
with the complete complement of vascular components
7 days after implantation (Figure 3A). The presence
of intralumenal red blood cells within the engineered
human microvessels evidenced successful anastomosis
with the local fascial vasculature and perfusion by
the host circulation (Figure 3A). The intra-scaffold
human vasculature was predominately functional at 14
and 21 days, displaying more uniform diameters and
intralumenal host-derived red blood cells (Figure 3B, C).
No anti-human CD31-staining vessels were detected in
sections from acellular or hPASMCs-only scaffold implants
(see Supporting information, Figure S1).
To ascertain the localization of the co-seeded hPaSMCs,
we conducted immunohistochemical analysis with anti-
α-SMC actin (α-SMA) and anti-human CD31 in co-
culture experiments with a HMVECs : hPaSMCs ratio
of 1 : 4. Tissue sections derived from 7 and 14 day
scaffold implants showed that anti-α-SMA staining cells
co-localized with patent human CD31-staining vessels,
likely representing co-seeded hPASMCs, as these time
points precede the invasion of host mural-derived cells
(Figure 4A, B) (Nor et al., 2001). The anti-α-SMA staining
cells became preferentially perivascular, encircling all
scaffold human vessels at 14 and 21 days post-
implantation (Figure 4B, C). Hence, co-seeded HMVECs
and hPASMCs adopt a native vessel configuration in the
in vivo tissue-engineering context.
3.2. hPASMCs enhance the formation of small
diameter microvessels in tissue-engineering
scaffolds
To determine whether vessel self-assembly in the in vivo
tissue-engineering context enhanced the formation of
small-calibre microvessels by the presence of hPASMCs,
we co-seeded HMVECs and hPASMCs at different ratios
(1 : 1, 1 : 4) or HMVECs alone (1 : 0) into Matrigel-
enriched PLLA scaffolds and evaluated vascularization
parameters following subcutaneous implantation. Sub-
cutaneous vascular cell implants were retrieved at
different time points from the immunodeficient host
Figure 1. HMVECs and hPASMCs form capillary-like networks in vitro. (A) Live cell fluorescence microscopy imaging of
a capillary-like network formed by GFP-expressing HMVECs after 5 days in co-culture (1 : 4) with hPASMCs (unlabelled).
(B) Localization of hPASMCs (anti-α-SMC/TRITC) in a 5 day co-culture with GFP–HMVECs. (C) Fluorescence microscopy analysis
of peri-endothelial collagen XVIII deposition (anti-collagen XVIII/TRITC) in GFP–HMVECs–hPASMCs (unlabelled) 5 day co-culture.
Scale bar = 50 µm
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Figure 2. PLLA scaffolds support cell attachment. Biocompatible and biodegradable poly-L-lactic acid (PLLA) scaffolds, produced
by a solvent-casting particulate-leaching technique, have a highly porous structure, with an average pore size of 400 µm. Scanning
electron microscope images, ×33 (A) and ×500 (B), show the deep pores penetrating the scaffold. (C) PLLA scaffolds support
cell attachment, as illustrated by a primary human vascular smooth muscle cell attaching to the wall of a scaffold pore. (D) A
subcutaneous PLLA scaffold seeded with human vascular cells 14 days post-implantation
Figure 3. Morphological and immunohistological analysis of scaffold microvasculature development. Scaffold implants were
excised at different time points and embedded in paraffin. Tissue sections were stained with anti-human CD31 and haematoxylin.
Longitudinal analysis of CD31-staining human microvessels formed within scaffolds seeded with HMVECs and hPASMCs (1 : 4) at
(A) 7 days, (B) 14 days and (C) 21 days post-implantation. The presence of intralumenal red blood cells within patent anti-CD31
stained vessels demonstrates that the engineered human microvessels are functional and perfused by the host blood circulation
(arrows, inset). Scale bar = 50 µm
Figure 4. Co-seeded smooth muscle cells are perivascularly localized. Anti-α-smooth muscle cell actin (α-SMA)-stained human
hPASMCs (arrows) are co-localized with anti-CD31-stained microvessels in HMVECs/hPASMCs (1 : 4) scaffolds 7 days
post-implantation (A). hPASMCs show increased perivascular localization in 14 day (B) and 21 day (C) scaffolds. Scale bar = 50 µm
mice and immunohistochemical morphometric analysis
was conducted to measure the human intra-scaffold
microvessel number and diameter. Microvessels were
assigned to five categories, based on the expected
diameter distribution of the microvasculature (Gray,
2004; Jenkins, 2007), <10, 10–20, 20–30, 30–50
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Figure 5. Smooth muscle cells enhance vessel maturation. Morphometric analysis of CD31-staining human microvessels formed
in scaffolds seeded with HMVECs only (black bars) or HMVECs–hPASMCs (1 : 1; grey bars) and HMVEC–hPASMCs (1 : 4; (white
bars) at 7 days post-implantation (A) show a predominance of 30–50 µm diameter vessels, indicative of a maturing vasculature.
After 14 days (B) the CD31-staining human microvessels decreased in calibre. The HMVEC–hPASMC-derived microvessels were
mainly 10–20 µm in diameter, representing a mature microvasculature. HMVECs alone remained distributed among larger-calibre
microvessels. After 21 days (C), the microvessels in all the scaffolds were predominately 10–20 µm in diameter. The 1 : 4
HMVECs : hPASMCs displayed a much larger percentage of small-calibre vessels. (D) The efficiency of microvascular formation
(microvascular density/250 000 HMVECs) was enhanced by the presence of hPASMCs. ∗p < 0.05; ∗∗p < 0.01
and >50 µm, where vessels >50 µm were defined as
immature vessels and vessels <10 µm and 10–20 µm
were defined as mature microvasculature. The remaining
size groups were defined as transitional. Analysis of 7 day
scaffolds showed that the vessels were mainly 30–50 µm
in diameter in all three vascular implants, indicative of
maturing, transitional microvasculature (Figure 5A). At
14 days post-implantation, the intra-scaffold microvas-
culature formed from the complete sets of vascular
components showed a strong shift in the vessel size distri-
bution to predominately 10–20 µm diameter microves-
sels, indicative of vessel maturation (Figure 5B). The
co-seeded HMVECs : hPASMCs (1 : 4) group showed an
increased proportion of <10 µm diameter microvessels,
demonstrating a greater degree of capillary-calibre ves-
sels (Figure 5B). This microvessel distribution remained
unchanged in the third week (Figure 5C) for co-seeded
implants. In contrast, implants lacking hPASMCs did
not show a commensurate microvessel size distribu-
tion shift until 21 days post-implantation, corresponding
to the invasion of host mural cells (Nor et al., 2001).
Notably, the efficiency of intra-scaffold microvascular for-
mation (microvascular density per seeded EC) in the
HMVEC : hPASMC (1 : 1 and 1 : 4) co-seeded scaffolds
was enhanced 2.5- and four-fold relative to HMVECs
alone at day 14 (Figure 5D). This is somewhat reduced
at day 21, likely reflecting perfusion-mediated vascular
remodelling. Collectively, these results indicate that a
complete complement of vascular components stimulates
the rapid formation and maturation of uniform small-
calibre microvessels in a tissue-engineering context in
vivo.
3.3. Analysis of tissue-engineered functional
microvasculature by fluorescence angiography
In order to functionally evaluate the intra-scaffold micro-
circulation engineered with the complete complement
of vascular components, we conducted a fluorescence
angiography analysis. UEA1–lectin conjugated to FITC,
which binds specifically to mannose moieties on the
luminal surface of human endothelial cells, was injected
into the host mouse circulation 30 min prior to sacri-
fice. To determine the presence of UEA1–lectin–FITC-
stained HMVECs that manifest an intra-scaffold microcir-
culation, we interrogated cells harvested from excised
14-day scaffolds by flow cytometry. A large popu-
lation of UEA1–lectin–FITC-stained cells were appar-
ent in the green fluorescence channel. These perfused
human endothelial cells exhibited high forward light scat-
ter values, indicating that larger, potentially elongated
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Figure 6. Functional analysis of scaffold microcirculation by fluorescence angiography. Animals were injected at 14 days
post-implantation with UEA–lectin–FITC 30 min prior to scaffold recovery to selectively label perfused human endothelial
cells. (A) Bivariate flow cytometry analysis of cells harvested from scaffolds. UEA–lectin–FITC fluorescence-positive cells (upper
box) correlated with higher forward light scatter (FSC) relative to non-staining cells (lower box). (B) Mean forward light scatter
(FSC) values of perfused UEA–lectin–FITC fluorescence-positive HMVECs vs non-staining cells. (C) Multiphoton fluorescence
microscopy image analysis (IMARIS) of perfusion-labelled UEA1–lectin–FITC human microvasculature within a 14 day scaffold
shows extensive branching of uniform microvessels. (D) Morphometric analysis of UEA1–lectin–FITC-stained human microvessels
from four independent experiments shows that functional microvessels were predominately 10–20 µm in diameter
endothelial cells comprise the functional microvascula-
ture (Figure 6A, B) (Ohnuma et al., 2006). In order
to further investigate the morphology of the perfused
vessels, we conducted a morphometric analysis of the
UEA1–lectin–FITC-stained human vessels in scaffolds by
multiphoton fluorescence microscopy. A series of flu-
orescence images were collected from 100 µm inside
vascularized scaffolds and reassembled by 3D image
analysis to determine the length and diameter of individ-
ual vessel branches of the functional microvasculature.
This UEA–lectin–FITC angiography analysis revealed
the presence of an extensive branched network of per-
fused human microvessels within scaffolds implanted for
14 days (Figure 6C). No UEA–lectin–FITC-staining was
detectable within 14 day acellular scaffolds or peripheral
mouse fascial vessels (see Supporting information, Figure
S1). The UEA–lectin–FITC-stained human endothelial
cells displayed abundant filapodia, consistent with ongo-
ing vessel remodelling. The perfused human vessels were
measured to be predominately <20 µm in diameter,
in accordance with the immunohistochemistry analysis
(Figures 5, 6D). Hence, tissue-engineering implants com-
prising a complete complement of vascular components
effectively self-assemble into a functional intra-scaffold
microvasculature that establishes a microcirculation with
the host.
In order to compare the location of the hPASMCs
relative to the perfused microvessels within the scaf-
fold, we studied scaffolds seeded with HMVECs and
RFP-expressing hPASMCs (hPASMC/RFP). After 2 weeks,
mice carrying HMVEC–hPASMC/RFP-seeded scaffolds
were injected with UEA–lectin–FITC. Following exci-
sion, the scaffolds were analysed for the presence of
RFP-expressing hPASMCs and UEA–lectin–FITC-stained
human endothelial cells by multiphoton fluorescence
microscopy at 100 µm depths. 3D image reconstruction
from multiphoton microscopy 3D image stacks revealed
that the majority of the hPASMC/RFP are located near
the perfused endothelial cells (Figure 7A, B). To quan-
titate this, volumetric pixel analysis of the 3D-image
stacks was performed. The analysis showed that the
hPASMCs were closer to the perfused endothelial cells
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Figure 7. Perfused vessels preferentially co-localize with smooth muscle cells within the scaffold. (A) Multiphoton fluorescence
microscopy 3D image analysis (IMARIS) of RFP-expressing hPASMCs and UEA1–lectin–FITC-stained human microvessels
within a 14 day scaffold. (B) Implanted RFP-expressing hPASMCs were frequently perivascularly localized. (C) Distribution of
distances (determined by Euclidean distance transformation) to the nearest hPASMC/RFP (red channel voxel) from functional
UEA1–lectin–FITC-stained human microvessels (green channel voxel) and all voxels within the 3D image. The measured mean
distance between perfused vessels and hPASMCs (22.6 ± 14.6 µm) was significantly smaller than would be expected for randomly
distributed vessels (43.1 ± 0.07 µm); p < 0.00001
than would be expected for a random distribution,
indicating co-localization (Figure 7C). hPASMC/RFP and
UEA1–lectin–FITC voxels within multiphoton microscopy
3D image stacks were separated by a mean distance of
22.6 ± 14.6 µm vs an expected random distribution mean
of 43.1 ± 0.07 µm (p < 0.0001). This is consistent with
the notion that hPASMCs enhance vessel maturation in the
tissue-engineering context by juxtapositional heterotypic
cell–cell interactions and paracrine signalling.
4. Discussion
A current challenge facing tissue-engineering approaches
is the expedient establishment of a microcirculation
to meet the metabolic needs of the developing tissue
implants and avoid cell death. We demonstrate here
that efficient self-assembly of a functional microvascu-
lature can be achieved in a physiological in vivo tissue-
engineering implant by providing individual vascular
cellular and basement membrane components. In par-
ticular, our results emphasize the critical role of vascular
mural cells in enforcing generation of a uniform, branched
functional microvasculature in a tissue-engineering
context.
The recruitment of mural cells to the abluminal
surface of nascent blood vessels is a key prerequisite
for vessel maturation (Jain, 2003). Mural cells define
a context comprising heterotypic cell–cell, cell–ECM
deposition contacts and juxtacrine growth factor receptor
signalling that regulate endothelial cell proliferation
and survival (Adams and Alitalo, 2007; Beck and
D’Amore, 1997; Carmeliet, 2003; Darland and D’Amore,
2001; Gaengel et al., 2009; Hellstrom et al., 2001; Jain,
2003; Korff et al., 2001). Proper growth factor receptor
crosstalk between EC–mural cells also engenders local
vascular basement membrane deposition required for
vessel maturation and stability (Davis and Senger,
2005). This perivascular microenviroment serves an
important role in delimiting endothelial responses to
pro-angiogeneic factors emanating from the local tissue
(Jain, 2003). Organotypic endothelial–vSMC co-culture
models demonstrate that paracrine mural cell-derived
VEGF is crucial to endothelial capillary-network-like
formation and that mural cell Ang-1 regulates endothelial
responsiveness to tissue-derived VEGF (Evensen et al.,
2010; Korff et al., 2001). This switch from tissue-
derived to mural cell-derived VEGF likely promotes vessel
maturation, ultimately leading to VEGF independence and
reduced vessel plasticity (Benjamin et al., 1998; Darland
and D’Amore, 2001). Importantly, recent studies show
that dysregulated tissue VEGF levels can affect mural cell
functions and inhibit vessel maturation (Greenberg et al.,
2008).
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Several previous studies have reported that mural cell
types enhance the stability of endothelial cells and the for-
mation of functional vessels in tissue implants (Au et al.,
2008; Koike et al., 2004; Melero-Martin et al., 2007; Shep-
herd et al., 2009). Congruently, we demonstrate that the
efficiency of intra-scaffold microvascular formation was
enhanced by the presence of vascular smooth muscle cells.
Indeed, a 1 : 4 EC : mural cell ratio of vascular progeni-
tor cells also generated the greatest vessel density within
Matrigel implants (Melero-Martin et al., 2008) A further
critical role of perivascular cells is to enforce diametral
uniformity in branched microvascular networks (Evensen
et al., 2009; Gerhardt and Betsholtz, 2003). Genetic and
pharmacological inhibition of mural cell recruitment to
growing vessels and is associated with exacerbated angio-
genesis and endothelial hypertrophy that form irregular,
enlarged vessels and aneurysms (Hellstrom et al., 2001;
Wilkinson-Berka et al., 2004). Mural cells exert vessel
morphogenic control both via modulating endothelial
cell signalling responses and contractile vasoconstric-
tion that collectively regulate haemodynamic parameters
(Gaengel et al., 2009; Gerhardt and Betsholtz, 2003).
Thus, to study vascularization in the tissue-engineering
setting, it is important to employ imaging approaches
to facilitate interrogation of the perfused microvascular
branched network architecture (Au et al., 2008; McDon-
ald and Choyke, 2003; Sanz et al., 2008). To address this
aspect, we utilized functional multiphoton microscopy to
selectively image the engineered microcirculation. The
acquisition of multiple, stacked images from function-
ally labelled scaffold implants facilitates imaged-based 3D
reconstruction and quanitification of spatial perivessel cel-
lular relationships. Analysis of 3D image reconstructions
demonstrated that hPASMCs preferentially co-localized
with perfused vessels. This is congruent with a pre-
vious study, where intra-vital multiphoton microscopy
through cranial windows showed that co-implanted mes-
enchymal stem cells acquired smooth muscle cell traits
and preferentially co-localized with perfused HUVECs
(Au et al., 2008). Together, these results highlight the
requisite role of proper spatial mural–endothelial cell
interactions in achieving a vascularized tissue-engineering
implant.
Earlier studies have demonstrated that increasing local
concentrations of VEGF in ischaemic tissues correlated
with increased vessel density but did not predict improved
tissue blood flow (Ozawa et al., 2004; von Degenfeld
et al., 2006). Instead, uniformity of vessel diameters was
the most important predictor of enhanced circulation,
emphasizing that vessel density measurements are insuffi-
cient predictors of angiogenic efficiency. Using functional
multiphotonic image analysis, we demonstrated that
the microcirculation within hPASMC/HMVEC implants
preferentially comprised highly branched, uniform small-
calibre vessels (<20 µm). In contrast, a recent study that
used Bcl-2-expressing human umbilical cord endothe-
lial cells (HUVECs) seeded in poly(glycolic acid) (PGA)
scaffold-supported protein gels found that co-engraftment
of hPASMCs led to an increase in large-calibre (>50 µm)
vessels (Shepherd et al., 2009). Hence, various com-
binations of heterogeneous vascular cells can retain a
propensity to form vessels of diverse sizes (Garlanda and
Dejana, 1997). These results emphasize the importance
of using functional morphometric imaging modalities
to interrogate engineered vessels formed by clinically
amenable endothelial and mesenchymal progenitor cells
that can acquire a spectrum of differentiated charac-
teristics (Au et al., 2008; Melero-Martin et al., 2007,
2008).
We conducted our experiments with native, early-
passage human vascular cells in the context of one
of the few FDA-approved (PLLA) tissue-engineering
scaffolds for medical implantation purposes (Freeman,
2007; Yun Chen, 2006). In order to promote initial cell
attachment, we prepared scaffold implants with Matrigel-
derived ECM proteins (laminin, collagen IV, entactin and
heparin sulphate proteoglycan). Using scanning electron
microscopy, we show that vascular cells can productively
adhere to the scaffold surface under these conditions.
The use of a scaffolding material and ECM gel provides
a biocompatible porous skeleton for cell attachment,
and therefore functions as a temporary ECM for the
implanted cells. The combination of PLLA and an ECM
protein gel comprises an engineered microenvironment
that is optimal for many applications, particularly where
resistance to compression or contraction is important, and
serves as a model for evaluating new cellular combinations
for tissue development (Shepherd et al., 2009).
In a recent study, we applied these concepts to
develop a tissue engineering-based tumour model
to enable evaluation of tumour–vasculature inter-
actions (Gjerdrum et al., 2010). Tricellular tumour
implants comprising human breast carcinoma, primary
microvascular endothelial and vascular smooth mus-
cle cells co-seeded into Matrigel-enriched PLLA scaf-
folds formed highly vascularized tumours. Interestingly,
the presence of a functional engineered microvascu-
lature at 2 weeks post-implantation corresponded with
enhanced tumour growth rate. However, in contrast to
the present study, only large-calibre diameter vessels
were formed (>80 µm). These results exemplify how
tissue-engineering approaches developed for regenera-
tive medicine applications afford new opportunities to
improve models of disease.
5. Conclusion
The efficient self-assembly of a functional microvascu-
lature in an in vivo tissue engineering context from
individual vascular components defines a conceptual
basis for improving contemporary tissue-engineering
approaches. The combination of immunohistochemical,
flow-cytometric and multiphotonic image analysis pro-
vides a methodological foundation for improved evalua-
tion of vascular parameters in bioengineered tissues.
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